- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05325866
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
-
Buenos Aires, Argentina, 1426
- Recruiting
- Centro Oncológico Korben
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina, C1426ANZ
- Recruiting
- Instituto Alexander Fleming
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1118AAT
- Recruiting
- Hospital Alemán
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1125ABD
- Recruiting
- Fundacion Cenit Para La Investigacion
-
La Plata, Buenos Aires, Argentina, 1900
- Recruiting
- Hospital Italiano de La Plata
-
-
Córdoba
-
Cordoba, Córdoba, Argentina, 5000
- Recruiting
- Sociedad de Beneficencia Hospital Italiano
-
-
Río Negro
-
Cipolletti, Río Negro, Argentina, 8324
- Recruiting
- Fundacion Medica de Rio Negro y Neuquen
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Recruiting
- Liverpool Hospital
-
Randwick, New South Wales, Australia, 2031
- Recruiting
- Prince of Wales Hospital
-
Wollongong, New South Wales, Australia, 2500
- Recruiting
- Wollongong Hospital
-
-
Queensland
-
Toowoomba, Queensland, Australia, 4350
- Recruiting
- Toowoomba Hospital
-
-
Victoria
-
Malvern, Victoria, Australia, 3144
- Recruiting
- Cabrini Hospital
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Recruiting
- St John of God Murdoch Hospital
-
-
-
-
-
Graz, Austria, 8036
- Recruiting
- Medizinische Universitaet Graz
-
Salzburg, Austria, 5020
- Recruiting
- Landeskrankenhaus Salzburg
-
-
-
-
-
Bruxelles, Belgium, 1200
- Recruiting
- Universite Catholique de Louvain Cliniques Universitaires Saint Luc
-
Charleroi, Belgium, 5530
- Recruiting
- Grand Hôpital de Charleroi
-
Edegem, Belgium, 2650
- Recruiting
- Universitair Ziekenhuis Antwerpen
-
Gent, Belgium, 9000
- Recruiting
- Universitair Ziekenhuis Gent
-
Leuven, Belgium, 3000
- Recruiting
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg
-
-
-
-
-
Rio de Janeiro, Brazil, 22250-905
- Recruiting
- Oncoclinicas Rio de Janeiro S A
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30130-100
- Recruiting
- Hospital Das Clinicas Da Ufmg
-
-
Paraná
-
Curitiba, Paraná, Brazil, 80440-220
- Recruiting
- Centro de Oncologia Mackenzie
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-001
- Recruiting
- Associacao Hospitalar Moinhos de Vento
-
-
São Paulo
-
Sao Paulo, São Paulo, Brazil, 01221-020
- Recruiting
- Instituto do Cancer Arnaldo Vieira de Carvalho
-
Sao Paulo, São Paulo, Brazil, 01323-900
- Recruiting
- Beneficencia Portuguesa de Sao Paulo
-
Sao Paulo, São Paulo, Brazil, 04501-000
- Recruiting
- Oncologia Rede D Or
-
-
-
-
-
Plovdiv, Bulgaria, 4000
- Recruiting
- Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
-
Plovdiv, Bulgaria, 4004
- Recruiting
- Complex Oncology Center Plovdiv EOOD
-
Sofia, Bulgaria, 1606
- Recruiting
- Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
-
-
-
-
-
Toronto, Canada, M5G 1Z5
- Recruiting
- Princess Margaret Cancer Centre
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- The Ottawa Hospital Cancer Centre
-
-
-
-
-
Brno, Czechia, 656 53
- Recruiting
- Masarykuv onkologicky ustav
-
Hradec Kralove, Czechia, 500 05
- Recruiting
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Czechia, 779 00
- Recruiting
- Fakultni nemocnice Olomouc
-
Praha 10, Czechia, 100 34
- Recruiting
- Fakultni nemocnice Kralovske Vinohrady
-
-
-
-
-
Kobenhavn O, Denmark, 2100
- Recruiting
- Rigshospitalet
-
-
-
-
-
Helsinki, Finland, 00180
- Recruiting
- Docrates Syopasairaala
-
Tampere, Finland, 33521
- Recruiting
- Tampere University Hospital
-
-
-
-
-
Angers Cedex 02, France, 49055
- Recruiting
- Institut de Cancerologie de l Ouest Rene Gauducheau
-
Besancon cedex, France, 25030
- Recruiting
- Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz
-
Lille Cedex, France, 59020
- Recruiting
- Centre Oscar Lambret
-
Marseille Cedex 09, France, 13272
- Recruiting
- Institut Paoli Calmettes
-
Montpellier Cedex 5, France, 34298
- Recruiting
- Institut régional du cancer Montpellier
-
Pierre-Benite, France, 69495
- Recruiting
- Centre Hospitalier Lyon Sud
-
Toulouse cedex 9, France, 31059
- Recruiting
- Institut Claudius Regaud
-
Villejuif, France, 94805
- Recruiting
- Institut Gustave Roussy
-
-
-
-
-
Athens, Greece, 11527
- Recruiting
- Sotiria General Hospital
-
Athens, Greece, 11528
- Recruiting
- Alexandra Hospital
-
Athens, Greece, 15562
- Recruiting
- Metropolitan General
-
Heraklion - Crete, Greece, 71500
- Recruiting
- University Hospital of Heraklion
-
Thessaloniki, Greece, 57001
- Recruiting
- European Interbalkan Medical Center
-
-
-
-
-
Budapest, Hungary, 1122
- Recruiting
- Orszagos Onkologiai Intezet
-
Budapest, Hungary, 1082
- Recruiting
- Semmelweis Egyetem
-
Nyiregyhaza, Hungary, 4400
- Recruiting
- Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaz
-
Szolnok, Hungary, 5000
- Recruiting
- Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet
-
-
-
-
-
Haifa, Israel, 3109601
- Recruiting
- Rambam Medical Center
-
Jerusalem, Israel, 9112001
- Recruiting
- Hadassah Ein-Kerem Medical Center
-
Petah Tikva, Israel, 4941492
- Recruiting
- Rabin Medical Center
-
Ramat Gan, Israel, 5262000
- Recruiting
- Sheba Medical Center
-
Tel Aviv, Israel, 6423906
- Recruiting
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Foggia, Italy, 71100
- Recruiting
- Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia
-
Mirano, Italy, 30035
- Recruiting
- Azienda Unità Locale Socio Sanitaria 3 Presidio Ospedaliero di Mirano
-
Napoli, Italy, 80147
- Recruiting
- Ospedale del Mare
-
Pisa, Italy, 56126
- Recruiting
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 464-8681
- Recruiting
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
-
Osaka
-
Osakasayama-shi, Osaka, Japan, 589-8511
- Recruiting
- Kindai University Hospital
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
Koto-ku, Tokyo, Japan, 135-8550
- Recruiting
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Seoul, Korea, Republic of, 138-736
- Recruiting
- Asan Medical Center
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital Yonsei University Health System
-
-
-
-
Baja California Sur
-
La Paz, Baja California Sur, Mexico, 23040
- Terminated
- Investigación Onco Farmacéutica S de RL de CV
-
-
Coahuila
-
Saltillo, Coahuila, Mexico, 25279
- Recruiting
- Centro de Infusion e Investigacion Oncologia de Saltillo
-
-
Distrito Federal
-
Ciudad de Mexico, Distrito Federal, Mexico, 03103
- Recruiting
- Investigación Biomédica para el Desarrollo de Fármacos
-
Mexico City, Distrito Federal, Mexico, 03100
- Recruiting
- Health Pharma Professional Research SA de CV
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64570
- Terminated
- Christus Muguerza Clinica Vidriera
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- Recruiting
- Universitair Medisch Centrum Groningen
-
Nijmegen, Netherlands, 6525 GA
- Recruiting
- Radboud Universitair Medisch Centrum
-
-
-
-
-
Krakow, Poland, 30-727
- Recruiting
- Pratia MCM Krakow
-
Lodz, Poland, 93-338
- Recruiting
- Instytut Centrum Zdrowia Matki Polki
-
Pila, Poland, 64-920
- Recruiting
- Ars Medical Spzoo
-
Siedlce, Poland, 08-110
- Recruiting
- Mazowiecki Szpital Wojewodzki im Sw Jana Pawla II w Siedlcach spzoo
-
Skorzewo, Poland, 60-185
- Recruiting
- Centrum Medyczne Pratia Poznan
-
-
-
-
-
Lisboa, Portugal, 1649-035
- Recruiting
- Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria
-
Lisboa, Portugal, 1500-650
- Recruiting
- Hospital da Luz, SA
-
Lisboa, Portugal, 1440-005
- Recruiting
- Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Sao Francisco Xavier
-
-
-
-
-
Cluj Napoca, Romania, 400015
- Recruiting
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
-
Craiova, Romania, 200347
- Recruiting
- Centrul de Oncologie Sf Nectarie SRL
-
Iasi, Romania, 700483
- Recruiting
- Institutul Regional de Oncologie Iasi
-
Timisoara, Romania, 300239
- Recruiting
- SC Oncomed SRL
-
-
-
-
Andalucía
-
Malaga, Andalucía, Spain, 29010
- Recruiting
- Hospital Clinico Universitario Virgen de la Victoria
-
-
Galicia
-
Santiago de Compostela, Galicia, Spain, 15706
- Recruiting
- Hospital Clinico Universitario de Santiago
-
-
-
-
-
Chur, Switzerland, 7000
- Recruiting
- Kantonsspital Graubuenden
-
Geneve, Switzerland, 1205
- Recruiting
- Hôpitaux universitaires de Genève
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- Recruiting
- Christie Hospital
-
Sheffield, United Kingdom, S10 2SJ
- Recruiting
- Weston Park Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope National Medical Center
-
Orange, California, United States, 92868
- Recruiting
- University of California Irvine
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Recruiting
- Rocky Mountain Cancer Centers
-
Denver, Colorado, United States, 80218
- Recruiting
- US Oncology Regulatory Affairs Corporate Office
-
Denver, Colorado, United States, 80218
- Recruiting
- US Oncology Research Investigational Products Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Completed
- Community Health Network MD Anderson Cancer Center - North
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Completed
- Henry Ford Hospital
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - Dallas Fort Worth
-
Houston, Texas, United States, 77030
- Completed
- University of Texas MD Anderson Cancer Center
-
Tyler, Texas, United States, 75702
- Recruiting
- Texas Oncology Northeast Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed
Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.
- head and neck squamous cell carcinoma: ≥ 1 line of therapy
- triple-negative breast cancer: ≥ 2 lines of therapy
- Intrahepatic cholangiocarcinoma ≥ 1 line of therapy
- lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy
- platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy
- endometrial adenocarcinoma: ≥ 1 line of therapy
- cervical carcinoma: ≥ 1 line of therapy
- other solid tumors: ≥ 1 line of therapy
- Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)
- Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing
- Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function as determined per protocol.
Exclusion Criteria:
- Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
- Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma
- Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction ≥ 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc ≥ 470
- History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids
- Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing
- Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment
- Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy
- Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Monotherapy Dose Exploration
Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive 1 of 2 dose regimens of bemarituzumab to determine recommended Phase 2 dose.
|
Intravenous (IV) infusion.
Other Names:
|
Experimental: Part 2: Monotherapy Dose Expansion
Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive the dose of bemarituzumab identified as the recommended Phase 2 dose during Part 1.
|
Intravenous (IV) infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Time Frame: Day 1 to Day 28
|
Day 1 to Day 28
|
|
Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Adverse events (AEs) are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment.
TEAEs are any event that occurs after the participant has received study treatment.
Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests that occur after study treatment administration will be recorded as TEAEs.
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
Part 1: Number of Participants Who Experience a Treatment-related Adverse Event
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
|
Part 2: Objective Response (OR) Rate
Time Frame: Up to approximately 2 years
|
OR = complete response (CR) + partial response (PR), measured by computed tomography (CT) or magnetic resonance imaging (MRI) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: OR Rate
Time Frame: Up to approximately 2 years
|
OR = CR + PR, measured by CT or MRI as determined by investigator per RECIST v1.1.
|
Up to approximately 2 years
|
Parts 1 and 2: Disease Control (DC) Rate
Time Frame: Up to approximately 2 years
|
DC = CR, PR, or stable disease (SD).
|
Up to approximately 2 years
|
Parts 1 and 2: Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
DOR, defined as the time from first documentation of OR (as determined by investigator per RECIST v1.1) until the first documentation of disease progression or death due to any cause, whichever occurs first.
Only participants who have achieved OR will be evaluated for DOR.
DOR will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy.
|
Up to approximately 2 years
|
Parts 1 and 2: Time to Response
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Parts 1 and 2: Progression-free Survival (PFS)
Time Frame: Up to approximately 2 years
|
PFS, defined as time from first dose of investigational product until the first documentation of radiologic disease progression or death due to any cause.
PFS will be censored at the last evaluable post-baseline tumor assessment prior to subsequent therapy.
Progression will be based on RECIST v1.1 (derived utilizing investigator tumor assessments).
|
Up to approximately 2 years
|
Parts 1 and 2: Overall Survival (OS)
Time Frame: Up to approximately 2 years
|
OS, defined as time from first dose of investigational product until death from any cause.
Participants still alive will be censored at the date last known to be alive.
|
Up to approximately 2 years
|
Part 2: Number of Participants Who Experience a TEAE
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
AEs are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment.
TEAEs are any event that occurs after the participant has received study treatment.
Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests that occur after study treatment administration will be recorded as TEAEs.
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
Part 2: Number of Participants Who Experience a Treatment-related AE
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
|
Parts 1 and 2: Area Under the Concentration Time Curve (AUC) of Bemarituzumab
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
|
Parts 1 and 2: Maximum Observed Serum Concentration (Cmax) of Bemarituzumab
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
|
Parts 1 and 2: Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab
Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years)
|
Day 1 to 28 days after last dose (a maximum of 2 years)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Head and neck squamous cell carcinoma
- Triple-negative breast cancer
- Bemarituzumab
- AMG 552
- Cervical carcinoma
- Epithelial solid tumors with fibroblast growth factor receptor 2b overexpression
- FGFR2b
- Intrahepatic cholangiocarcinoma
- Lung adenocarcinoma
- Ovarian epithelial carcinoma
- Endometrial adenocarcinoma
- Other solid tumors
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20210104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on Bemarituzumab
-
Five Prime Therapeutics, Inc.No longer available
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the BladderKorea, Republic of, United States, Taiwan
-
AmgenCompletedGastric or Gastroesophageal CancerJapan
-
AmgenZai Lab (China only)RecruitingGastric Cancer | Gastroesophageal Junction AdenocarcinomaCanada, China, Japan, United States, Korea, Republic of, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Portugal, Romania, Chile, Malays... and more
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer MetastaticUnited States
-
Five Prime Therapeutics, Inc.Zai Lab (Shanghai) Co., Ltd.CompletedGastric CancerUnited States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom
-
AmgenRecruitingGastric Cancer | Gastroesophageal Junction AdenocarcinomaKorea, Republic of, United States, Israel, Italy, Spain, Australia, Germany, United Kingdom, Austria, France, Japan, Switzerland, Taiwan, Belgium, Poland, China, Thailand, Canada, Czechia, Singapore, Hungary, Argentina, Brazil, Portugal, Roman... and more
-
AmgenRecruitingGastric Cancer | Gastroesophageal Junction CancerKorea, Republic of, Taiwan, Japan, Singapore, United States
-
University of ChicagoAbbVieCompleted
-
AmgenActive, not recruitingSquamous-Cell Non-Small-Cell Lung CancerFrance, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland